![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, November 07, 2014 11:52:52 AM
"For Ebola, we recently announced submission of our protocol to apply INTERCEPT to the treatment of Ebola convalescent plasma. Plasma collected from individuals who have recovered from Ebola virus disease contain antibodies against the virus, these antibodies that can help fight Ebola infections in the recipient of the transfused plasma. Convalescent plasma has demonstrated benefit in prior disease outbreaks, and is one of the few therapies immediately available for Ebola virus disease. It is of note that each of the surviving patients treated in the U.S. received convalescent plasma during the active phase of their disease. A concern associated with collection of convalescent plasma from recovered patients is that they may carry undetected pathogens due to prior exposure, and their history of travel to Africa make these individuals temporarily ineligible to donate blood under U.S. regulatory guidelines. We believe that INTERCEPT pathogen inactivation can provide a critical risk mitigation strategy by inactivating harmful organisms that may be present without impacting the anti-Ebola antibodies that the patient needs."
Recent CERS News
- Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion • Business Wire • 06/21/2024 12:30:00 PM
- Cerus Corporation Celebrates World Blood Donor Day 2024 • Business Wire • 06/14/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:03:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 12:03:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 12:02:04 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 12:00:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:59:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:58:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:57:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:54:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 11:52:59 PM
- Form SD - Specialized disclosure report • Edgar (US Regulatory) • 05/31/2024 08:01:50 PM
- Cerus Corporation to Participate in 21st Annual Craig-Hallum Institutional Investor Conference • Business Wire • 05/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2024 10:30:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 09:09:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/11/2024 12:17:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/09/2024 09:15:17 PM
- Cerus Corporation Announces First Quarter 2024 Financial Results • Business Wire • 05/02/2024 08:00:00 PM
- Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024 • Business Wire • 04/18/2024 12:30:00 PM
- Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life • Business Wire • 03/26/2024 12:30:00 PM
- Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients • Business Wire • 03/19/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:46:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:23:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:22:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 11:20:43 PM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM